STOCK TITAN

SciSparc (NASDAQ: SPRC) converts debentures into shares, updates float

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

SciSparc Ltd. reports that in August 2025 certain investors converted portions of previously issued convertible debentures into equity. The debentures were originally issued in an aggregate principal amount of $4.2 million and are convertible into ordinary shares. Based on conversion notices submitted by investors, the company issued 999,528 ordinary shares upon conversion of outstanding principal and accrued interest. After these issuances, SciSparc had 1,622,273 ordinary shares issued and outstanding as of August 28, 2025, and $175,000 principal amount of debentures remained outstanding.

Positive

  • None.

Negative

  • None.

Insights

Debt converts to equity, increasing share count while reducing debenture balance.

The company initially issued convertible debentures with an aggregate principal of $4.2 million, convertible into ordinary shares at a purchase price equal to 95% of the subscription amount. In August 2025, investors exercised conversion rights, resulting in the issuance of 999,528 ordinary shares in exchange for outstanding principal and accrued interest.

Following these conversions, ordinary shares issued and outstanding rose to 1,622,273 as of August 28, 2025, while the remaining debenture principal fell to $175,000. This shifts part of the company’s capital structure from debt to equity, which can reduce future interest obligations but also increases the number of shares outstanding. Subsequent disclosures may provide further detail on any additional conversions or changes to the remaining debentures.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of August 2025 (Report No. 5)

 

Commission File Number: 001-38041

 

SCISPARC LTD.

(Translation of registrant’s name into English)

 

20 Raul Wallenberg Street, Tower A,

Tel Aviv 6971916 Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒    Form 40-F ☐

 

 

 

 

 

 

CONTENTS

 

As previously reported in a Report of Foreign Private Issuer on Form 6-K on February 27, 2025, SciSparc Ltd. (the “Company”) entered into securities purchase agreements with certain investors (the “Investors”), dated February 25, 2025, pursuant to which the Company agreed to sell and issue to the Investors convertible debentures (the “Debentures”) in the aggregate principal amount of $4.2 million (the “Subscription Amount”), which are convertible into the Company’s ordinary shares, no par value per share (the “Ordinary Shares”), at a purchase price equal to 95% of the Subscription Amount.

 

In August 2025, certain of the Investors submitted to the Company notices of conversion (the “Conversion Notices”) to convert outstanding principal and accrued interest of the Debentures, pursuant to which the Company issued an aggregate of 999,528 Ordinary Shares to such investors. Following the issuances made by the Company pursuant to the Conversion Notices, as of the close of business on August 28, 2025, the Company had 1,622,273 Ordinary Shares issued and outstanding.

 

As of the close of business on August 28, 2025, an aggregate principal amount of $175,000 of the Debentures remains outstanding.

 

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670 and 333-255408) and on Form S-8 (File Nos. 333-278437, 333-225773 and 333-286791) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  SciSparc Ltd.
     
Date: August 29, 2025 By: /s/ Oz Adler
  Name:  Oz Adler
  Title: Chief Executive Officer and Chief Financial Officer

 

 

2

 

FAQ

What debentures did SciSparc (SPRC) originally issue?

SciSparc issued convertible debentures in an aggregate principal amount of $4.2 million, which are convertible into its ordinary shares at a price equal to 95% of the subscription amount.

How many SciSparc (SPRC) shares were issued upon debenture conversion?

In August 2025, SciSparc issued an aggregate of 999,528 ordinary shares to certain investors upon conversion of outstanding debenture principal and accrued interest.

What is SciSparc’s (SPRC) total ordinary shares outstanding after the conversions?

Following the August 2025 conversions, SciSparc had 1,622,273 ordinary shares issued and outstanding as of the close of business on August 28, 2025.

How much of SciSparc’s (SPRC) debentures remain outstanding?

As of the close of business on August 28, 2025, an aggregate principal amount of $175,000 of the convertible debentures remained outstanding.

Are these debenture conversions linked to SciSparc’s existing registration statements?

Yes. This report is incorporated by reference into SciSparc’s Form F-3 and Form S-8 registration statements identified by their file numbers with the Securities and Exchange Commission.
Scisparc

NASDAQ:SPRC

View SPRC Stock Overview

SPRC Rankings

SPRC Latest News

SPRC Latest SEC Filings

SPRC Stock Data

2.26M
517.11k
Biotechnology
Healthcare
Link
Israel
Tel Aviv-Yafo